Straits Times Index
3,320.12 -1.96 (-0.06%) Nikkei
39,164.95 +126.79 (+0.32%) Hang Seng
18,182.09 -184.86 (-1.01%) FTSE 100
8,228.48 -16.89 (-0.20%) Bitcoin USD
69,383.21 -257.25 (-0.37%) CMC Crypto 200
1,438.89 -7.79 (-0.54%)
Acticor Biotech SAS (ALACT.PA)
- Business Wire
Acticor Biotech Updates Its Glenzocimab Clinical Development Plan for the Treatment of Cardiovascular Emergencies
PARIS, June 03, 2024--Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, provides an update on the clinical development of glenzocimab following the release of results from its phase 2/3 ACTISAVE study.
- Business Wire
Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of April 30, 2024
PARIS, May 27, 2024--Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today discloses the total number of voting rights and shares as of April 30, 2024 (pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority).
- Business Wire
ACTICOR BIOTECH: Presentation of the Main Results of the Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024
PARIS, May 15, 2024--Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, including stroke, announces the presentation, on Wednesday, May 15, 2024 during the opening session of the 10th European Stroke Organisation Conference (ESOC), of the phase 2/3 study results, ACTISAVE, in the treatment of acute ischemic stroke.
